LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced Curtis Rambaran, MD, previously Silence’s Vice President, Head of Clinical Science, has been promoted to Chief Medical Officer, and Marie Wikström Lindholm, PhD, previously Silence’s Senior Vice President, Head of Molecular Design, has been promoted to Chief Scientific Officer, effective immediately..

伦敦-（商业线）-纳斯达克股票代码Silence Therapeutics plc:SLN（“Silence”或“Company”）是一家经验丰富且创新的生物技术公司，致力于通过精密工程药物沉默疾病来改变人们的生活，Curtis Rambaran医学博士，此前曾是Silence的临床科学副总裁兼，曾被提升为首席医疗官，之前Silence的分子设计负责人高级副总裁MarieWikströmLindholm博士已被提升为首席科学官，立即生效。。

“I want to congratulate Curtis and Marie on their well-deserved promotions,” said Steven Romano, MD, Head of Research and Development at Silence. “Both have been instrumental to our clinical and scientific successes to date. Curtis’ broad experience leading successful early and late-stage development programs combined with his background in cardiovascular medicine will be invaluable to Silence’s next phase of growth.

“我想祝贺柯蒂斯和玛丽在他们应得的晋升上的表现，”沉默研究与发展总监史蒂文·罗马诺博士说。“迄今为止，两者都为我们的临床和科学成功做出了贡献。柯蒂斯领导成功的早期和晚期发展计划的广泛经验，加上他在心血管医学方面的背景，对于沉默下一个发展阶段将是无价的。

With our expanding mRNAi GOLD™ platform programs and commitment to advancing scientific research, I am also looking forward to continuing to collaborate closely with Marie. Her extensive work in oligonucleotide therapeutics is impressive and we are very fortunate to have her leading our efforts to innovate and further expand our footprint as a global siRNA leader.”.

随着我们不断扩大的mRNAi黄金™平台计划和致力于推进科学研究，我也期待继续与玛丽密切合作。她在寡核苷酸治疗方面的广泛工作令人印象深刻，我们非常幸运地领导我们的努力，以创新和进一步扩大我们作为全球siRNA领导者的足迹“。

About Curtis Rambaran, MD

关于柯蒂斯·兰巴兰，医学博士

Curtis Rambaran joined Silence Therapeutics as VP and Head of the Clinical Science group in January 2021. He has 15 years’ experience in drug development across large pharma, medium sized pharma and recently biotech, spanning early and late-stage programs in cardiovascular, respiratory and rare diseases.

Curtis Rambaran于2021年1月加入Silence Therapeutics担任副总裁和临床科学小组负责人。他在大型制药，中型制药和最近的生物技术领域拥有15年的药物开发经验，涵盖心血管，呼吸系统和罕见疾病的早期和晚期项目。

Curtis joined the Respiratory Translational Medicine team at GlaxoSmithKline (GSK) in 2009 developing first in human and experimental medicine studies for novel oral and inhaled cardiopulmonary assets. He then moved to late phase development to work on several cardiovascular outcome studies (CVOTs) with novel anti-inflammatory MOA including LpPLA2 and p38 MAPK inhibitors.

柯蒂斯于2009年加入葛兰素史克（GSK）的呼吸转化医学团队，为新型口服和吸入心肺资产开发首次人体和实验医学研究。然后，他转向后期开发，开展了几项心血管预后研究（CVOT），其中包括新型抗炎MOA，包括LpPLA2和p38 MAPK抑制剂。

Following this, he became European Head of Translational Medicine and Clinical Pharmacology at Daiichi Sankyo UK, transitioning a year later to work with the New Jersey-based team in the US, leading early development programs across cardio-renal and rare diseases. This included human induced pluripotent stem cells for heart failure, NaPi-IIb inhibition for hyperphosphatemia in chronic kidney disease and an RNA antisense oligonucleotide for Duchenne Muscular Dystrophy..

此后，他成为英国第一三共公司转化医学和临床药理学的欧洲负责人，一年后过渡到美国新泽西州的团队工作，领导心肾和罕见疾病的早期发展计划。这包括用于心力衰竭的人诱导多能干细胞，用于慢性肾病中高磷血症的NaPi-IIb抑制和用于Duchenne肌营养不良症的RNA反义寡核苷酸。。

Prior to joining industry, Curtis received a prestigious Wellcome Trust Cardiology Research Fellowship at King’s College University of London, followed by a specialist training program in Cardiovascular Medicine and Clinical Pharmacology at Guy’s & St Thomas’ Hospital London, UK. Preceding this, he completed an Internal Medicine residency in Yorkshire, UK after graduating with a medical degree from the University of the West Indies.

在加入行业之前，柯蒂斯在伦敦国王学院获得了着名的威康信托心脏病研究奖学金，随后在英国伦敦盖伊和圣托马斯医院接受了心血管医学和临床药理学专业培训计划。在此之前，他完成了约克郡的内科住院医师，英国西印度群岛大学获得医学学位后毕业。

He has led several academic-industry collaborations and published in peer-reviewed journals on vascular structure and function, cardiac safety, hypertension and clinical pharmacology..

他领导了几项学术界合作，并在同行评审的期刊上发表了关于血管结构和功能，心脏安全性，高血压和临床药理学的文章。。

About Marie Wikström Lindholm, PhD

关于Marie Wikström Lindholm，博士

Marie Wikström Lindholm joined Silence in December 2017. She has more than 15 years’ experience with oligonucleotide therapeutics, starting with Santaris Pharma A/S, Denmark, working on locked nucleic acid (LNA) oligonucleotide drug discovery from molecule design through in vitro screening, in vivo activity and metabolism studies, and finally a role as lipid metabolism expert.

MarieWikströmLindholm于2017年12月加入沉默。从丹麦Santaris Pharma A/S开始，她在寡核苷酸治疗方面拥有超过15年的经验，致力于从分子设计到体外筛选，体内活性和代谢研究的锁核酸（LNA）寡核苷酸药物发现，以及最后作为脂质代谢专家的角色。

When Santaris was acquired by Roche in 2014, she was appointed Expert Scientist in Discovery Technology and Head of Targeted Delivery of oligonucleotide conjugates. She was also scientific coordinator for the LNA work in two large EU-funded FP7 programs (AtheroBCell and AtheroFlux). Before the transition to industry, she had an international academic career in experimental cardiovascular research starting with a PhD from Uppsala University.

当Santaris于2014年被罗氏收购时，她被任命为发现技术专家科学家和寡核苷酸偶联物靶向递送负责人。她还是欧盟资助的两个大型FP7项目（AtheroBCell和AtheroFlux）LNA工作的科学协调员。在过渡到工业之前，她从乌普萨拉大学获得博士学位开始，在实验性心血管研究方面拥有国际学术生涯。

She has authored over 60 patents and peer-reviewed scientific publications, many in the fields of oligonucleotide drug design, safety, and function..

她撰写了60多项专利和同行评审的科学出版物，其中许多涉及寡核苷酸药物设计，安全性和功能领域。。

About Silence Therapeutics

关于沉默疗法

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity.

沉默疗法正在利用人体RNA干扰的自然机制或RNAi来开发新一代药物，以抑制被认为在具有显着未满足需求的疾病的病理学中起作用的特定靶基因的表达。Silence专有的mRNAi黄金™平台可用于创建siRNA（短干扰RNA），精确靶向和沉默肝脏中与疾病相关的基因，这是一个巨大的机会。

Silence's wholly owned product candidates include zerlasiran designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others.

Silence的合资产品候选人包括zerlasiran，旨在解决高水平脂蛋白（a）和SLN124旨在解决血液疾病的人降低心血管风险的高度和普遍未满足的医疗需求。Silence还与AstraZeneca，Mallinckrodt Pharmaceuticals和Hansoh Pharma等公司保持持续的研发合作。

For more information, please visit https://www.silence-therapeutics.com/..

欲了解更多信息，请访问https://www.silence-therapeutics.com/..

Forward-Looking Statements

前瞻性声明

Certain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company’s cash runway and forecast operating cash flow, the Company’s clinical and commercial prospects, regulatory approvals of the Company’s product candidates, potential partnerships or collaborations or payments under new and existing collaborations, the initiation or completion of the Company’s clinical trials and the anticipated timing or outcomes of data reports from the Company’s clinical trials.

本公告中所作的某些陈述是1995年“美国私人证券诉讼改革法”及其他证券法（包括公司现金跑道和预测经营现金流量，公司临床和商业前景，公司产品候选人的监管批准，新合作和现有合作下的潜在合作伙伴关系或合作或支付，公司临床试验的启动或完成以及公司临床试验数据报告的预期时间或结果。

These forward-looking statements are not historical facts but rather are based on the Company's current assumptions, beliefs, expectations, estimates and projections about its industry. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” and similar expressions are intended to identify forward-looking statements.

这些前瞻性陈述不是历史事实，而是基于公司目前对其行业的假设，信念，期望，估计和预测。诸如“预期”，“期望”，“打算”，“计划”，“相信”，“寻求”，“估计”之类的词语旨在识别前瞻性陈述。

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company’s most recent Admission Document and its Annual Report on Form 20-F filed with the U.S.

这些陈述不能保证未来的业绩，并受到已知和未知的风险，不确定性和其他因素的影响，其中一些因素超出公司的控制范围，难以预测，并可能导致实际结果与表达或预测的结果大不相同。在前瞻性陈述中，包括本公司最新录取文件及其提交给美国的表格20-F年度报告中确定的风险。

Securities and Exchange Commission on March 15, 2023. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the da.

2023年3月15日证券交易所。本公司警告担保人和潜在担保人不要过分依赖这些前瞻性声明，这些声明仅在本公告发布之日起反映本公司的观点。本公告中提出的前瞻性声明仅涉及截至da的事件。